A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Leucostim 5µg/kg/day|BIOLOGICAL: Neupogen 5µg/kg/day
Sponsor: Dong-A ST Co., Ltd.